Islet cell function: α and β cells - Partners towards normoglycaemia

International Journal of Clinical Practice

Volumn 62, Issue SUPPL. 159, 2008, Pages 2-7

  Goke B ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

CELL FUNCTION; CELL LOSS; DIET RESTRICTION; DOWN REGULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESPONSE; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; ANIMAL; DIABETES MELLITUS; METABOLISM; PANCREAS ISLET; PHYSIOLOGY; POSTPRANDIAL STATE;

ANIMALS; DIABETES MELLITUS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-SECRETING CELLS; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; POSTPRANDIAL PERIOD;

EID: 38949125456     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01686.x     Document Type: Review

References (22)

1. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975 1 : 14 6.
2. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995 16 : 390 410.
3. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006 49 : 253 60.
4. Weyer C, Bogardus C, Mott DM et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999 104 : 787 94.
5. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med 1971 285 : 443 9.
6. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. N Engl J Med 1970 283 : 109 15.
7. MacDonald PE, El-kholy W, Riedel MJ, Salapatek AMF, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002 51 (Suppl. 3 S434 42.
8. Utzschneider KM, Porte D Jr., Kahn SE (2004) Normal insulin secretion in humans. In : DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds. International Textbook of Diabetes. 3rd edn. New York, NY : John Wiley and Sons, pp. 139 51.
9. Deng S, Vatamaniuk M, Huang X et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004 53 : 624 32.
10. Yoon KH, Ko SH, Cho JH et al. Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003 88 : 2300 8.
11. Weir GC, Bonner-Weir S (1996) Insulin secretion in non-insulin dependent diabetes mellitus. In : LeRoith DL, Taylor SI, Olefsky JM, eds. Diabetes Mellitus. Philadelphia, PA : Lipincott-Raven, pp. 503 8.
12. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contribution of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989 38 : 387 95.
13. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976 42 : 222 9.
14. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001 24 : 539 48.
15. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005 48 : 1700 13.
16. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003 284 : E671 8.
17. 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996 97 : 126 32.
18. Liljenquist JE, Mueller GL, Cherrington AD et al. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977 59 : 369 74.
19. Kelley D, Mokan M, Veneman T. Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism 1994 43 : 1549 57.
20. Ward WK, Bolgiano DC, McKnight B, Halkter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984 74 : 1318 28.
21. Schirra J, Sturm K, Leicht P et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998 101 : 1421 30.
22. Ristic S, Bates PC. Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Drugs Today (Barc) 2006 42 : 519 31.